Cipla

In News

Cipla recalls UTI drug in US - pharma.economictimes.indiatimes.com

pharma.economictimes.indiatimes.com - Oct 15, 2026

India's Cipla posts another profit decline, names insider Dinesh Jain CFO - Reuters

Reuters - Jul 23, 2026

Cipla Receives U.S. FDA Approval for Generic Advair Diskus® - PR Newswire

PR Newswire - Jul 28, 2026

Cipla Recalls UTI Treatment Drug Fosfomycin Tromethamine Granules in US - Medical Dialogues

Medical Dialogues - Oct 15, 2026

CIPLA: Broad Emerging Market Demand Still Matters, Chronic And U.S. Complexity Matter More - Simply Wall Street

Simply Wall Street - Oct 09, 2026

Cipla Ltd (BOM:500087) Q1 2027 Earnings Call Highlights: Strong Start with Record Revenue ... - Yahoo Finance

Yahoo Finance - Jul 24, 2026

FDA cancels drug sale licences of Cipla Pharma & Life Sciences' Pune Carry and Forwarding unit - The Hindu

The Hindu - Aug 28, 2026

Maha FDA Hits Cipla Again with New Cancellation Order - TradingView

TradingView - Oct 02, 2026

Cipla partners with Qilu Pharmaceutical for Keytruda biosimilar, launches generic Pomalyst - Drug Store News

Drug Store News - Sep 17, 2026

Lilly Sues Cipla to Block Copy of Breast Cancer Drug Verzenio - Bloomberg Law News

Bloomberg Law News - Jun 15, 2026

Cipla, Qilu Enter Licensing and Supply Deal for Keytruda Biosimilar in US - Contract Pharma

Contract Pharma - Sep 03, 2026

Cipla Partners With Qilu Pharmaceutical to Commercialize a Keytruda Biosimilar in the US - BioPharm International

BioPharm International - Sep 04, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment